Another interleukin, IL6 has also been implicated in pancreatic cancer and has been shown to be associated with a poorer prognosis36 and disease progression,37 and its receptor is being explored as a potential drug target for the disease.38 This evidence concerns the gene IL6 and familial pancreatic carcinoma.